MetrioPharm AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 16
- Market Cap
- -
- Website
- http://www.metriopharm.ch
Clinical Trials
12
Active:9
Completed:3
Trial Phases
2 Phases
Phase 1:9
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 1
9 (75.0%)Phase 2
3 (25.0%)MP1032 Treatment in Patients With Moderate to Severe COVID-19
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- MetrioPharm AG
- Target Recruit Count
- 132
- Registration Number
- NCT04932941
- Locations
- 🇺🇸
Snake River Research PLLC, Idaho Falls, Idaho, United States
🇺🇸Richmond University Medical Center, Staten Island, New York, United States
🇧🇬MHAT Blagoevgrad AD, Blagoevgrad, Bulgaria
Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis
- First Posted Date
- 2018-10-15
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- MetrioPharm AG
- Target Recruit Count
- 155
- Registration Number
- NCT03706209
- Locations
- 🇩🇪
Dr. Tsianakas / Dr. Ameluxen, Bad Bentheim, Germany
🇩🇪Rothaar Studien GmbH, Berlin, Germany
🇩🇪Dr. Johannes Niesmann / Dr. Othlinghaus, Bochum, Germany
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- MetrioPharm AG
- Target Recruit Count
- 46
- Registration Number
- NCT02908347
- Locations
- 🇩🇪
Rothaar Studien GmbH, Berlin, Germany
🇩🇪PAREXEL International GmbH, Klinikum Westend, Berlin, Germany
🇩🇪Klinische Forschung Dresden GmbH, Dresden, Germany
News
No news found